Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration
Open Access
- 1 March 2005
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (3) , 312-315
- https://doi.org/10.1136/bjo.2004.050997
Abstract
Aim: To determine if photodynamic therapy (PDT) outcomes are related to lesion size in patients with subfoveal predominantly classic choroidal neovascularisation (CNV) secondary to age related macular degeneration (AMD). Methods: According to greatest linear dimension (GLD) of the entire lesion determined with fluorescein angiography (FA) patients were divided into two groups. In the first group GLD was 1000 μm was recorded in nine eyes (28.1%) in the group of smaller lesions and in 16 eyes (50%) in the group of larger lesions (p = 0.07). 22 eyes (68.7%) in the group of smaller lesions compared with 19 eyes (59.3%) in the group of larger lesions lost less than three lines of vision (p = 0.06). Relevant side effects related to verteporfin therapy were not recorded, except for four patients (6.2%) with infusion related back pain. Conclusions: These results suggest that lesion size at baseline may be a prognosis factor in PDT in patients with subfoveal predominantly classic CNV secondary to AMD. There are no relevant side effects or safety concerns derived from verteporfin therapy.Keywords
This publication has 14 references indexed in Scilit:
- Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patternsAmerican Journal of Ophthalmology, 2004
- VERTEPORFIN THERAPY OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATIONRetina, 2004
- Photodynamic Therapy of Subfoveal Choroidal Neovascularization With VerteporfinArchives of Ophthalmology (1950), 2003
- Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluationHealth Technology Assessment, 2003
- Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Patients With Age-Related Macular DegenerationArchives of Ophthalmology (1950), 2002
- GUIDELINES FOR USING VERTEPORFIN (VISUDYNE®) IN PHOTODYNAMIC THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSESRetina, 2002
- Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne)British Journal of Ophthalmology, 2002
- The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degenerationOphthalmology, 2001
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2American Journal of Ophthalmology, 2001
- Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With VerteporfinArchives of Ophthalmology (1950), 1999